1. Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey
- Author
-
Stefania Mancini, Paolo Perseghin, Annino Pandolfi, Martino Introna, Monia Marchetti, Marco Risso, Pietro Leoni, Patrizia Accorsi, Luca Pierelli, Alberto Bosi, Attilio Olivieri, Alessandro Rambaldi, Jacopo Olivieri, Elisa Gotti, and Simone Dal Pozzo
- Subjects
Cancer Research ,medicine.medical_specialty ,long-term storage ,medical waste disposal ,medicine.medical_treatment ,Immunology ,Cell- and Tissue-Based Therapy ,CD34 ,Hematopoietic stem cell transplantation ,Cryopreservation ,Autologous stem-cell transplantation ,medicine ,Humans ,Immunology and Allergy ,biological specimen banks ,cryopreservation ,hematopoietic stem cell transplantation ,hematopoietic progenitor cells ,Autografts ,Genetics (clinical) ,Transplantation ,Acute leukemia ,business.industry ,Hematopoietic stem cell ,Cell Biology ,Hematopoietic Stem Cells ,Surgery ,medicine.anatomical_structure ,Oncology ,Cohort ,Stem cell ,business ,Stem Cell Transplantation - Abstract
Background aims Hematopoietic stem cell cryopreservation significantly contributed to autologous stem cell transplantation (ASCT). Cryopreserved stem cell units (SCU) are expected to be used soon after harvesting for most purposes, but, in a number of cases, they remain stored for some time, creating an increasing load for SCU depositories. Disposal policies vary widely in each center, and the existing guidelines are insufficient. Methods We conducted a survey of seven Gruppo Italiano Trapianto di Midollo Osseo centers to investigate the outcome of SCU harvested from January 2005 to December 2009 for ASCT. The data from 1603 collections were gathered, for a total of 5822 SCU. Results In our cohort, 79% of patients collected >5 × 10 6 CD34+ cells/kg, and 3.4% collected 6 CD34+ cells/kg. Up to 21% of all the patients and 42% of those with acute leukemia did not undergo reinfusion, and 37% of the cryopreserved SCU were excess, resulting from patients not reinfusing or partially reinfusing. Less than one-third of the excess SCU was disposed, and the major causes of disposal were death and, in a minority of cases, withdrawal of the indication for ASCT. In our analysis, very few first reinfusions occurred after 2 years, and those after 5 years were exceptional. Through the use of a multivariate analysis, we sought to identify the risk factors for collection non-use, independent of the centers' policies. Non-use of SCU was significantly associated with patients with acute leukemia, collections of 6 CD34/kg and lower age groups. Conclusions These data serve as a valid basis to support rational recommendations for cost-effective storage and disposal of SCU.
- Published
- 2014
- Full Text
- View/download PDF